New product launches has been the most dominating strategy adopted by major players in Pacemakers Market
The pacemakers
market is projected to reach USD 4.9 billion by 2023 from USD 4.4 billion
in 2018, at a CAGR of 2.0% during the forecast period. The major driving
factors in the pacemakers market are increasing prevalence of cardiovascular
diseases and technological advancements in devices.
The major pacemakers vendors include Medtronic (Ireland),
Abbott (US), and Boston Scientific (US) BIOTRONIK (Germany), LivaNova (UK),
OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and
Lepu Medical (China). These players have adopted various growth strategies such
as expansions, acquisitions, and new product launches to expand their presence
in the global pacemakers market. Product launches has been the most dominating
strategy adopted by major players from 2015 to 2018. This has helped them to
expand their consumer base and address the unmet needs of end users.
In line with rising adoption of pacemaker devices,
Medtronic focus on to develop innovative products for the treatment of heart
rhythm disorders and heart failures. The company offers an extensive product
portfolio for this market through its Cardiac and Vascular Group segment. It
has a significant presence in more than 155 countries including major markets
such as the US and Ireland. Medtronic focuses on organic growth strategies such
as product launches to remain competitive in the market. In the last three
years, it launched several products such as the Advisa and Ensura SR MRI
SureScan Single-chamber Pacemaker Devices, Viva CRT-P Pacemaker, and Advisa DR
MRI SureScan Pacing System.
In 2017, Abbott acquired of St Jude Medical, this acquisition
strengthened Abbott’s product offerings in the cardiovascular devices segment
including pacemakers. The company offers a wide range of pacemaker products for
cardiac rhythm management applications. Abbott is focusing on inorganic and
organic growth strategies such as acquisitions and product launches. For
example, in 2018, the company launched its smallest pacemaker, Assurity MRI and
also receive CE mark approval for Nanostim leadless pacemaker in 2016. The
company has a vast geographic presence and operated in 150 countries across the
world. Abbott’s strong portfolio provides it with a competitive advantage in
the market.
Related Reports:
Pacemakers Market by Implantability (External),
Technology (Single Chamber, Dual Chamber, CRT-P/Biventricular Pacemaker), Type
(Conventional, MRI Compatible), End User (Hospitals and Cardiac Centers,
Ambulatory Surgical Center) - Global Forecast to 2023
Comments
Post a Comment